Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited
Key Takeaways
- Wegovy is semaglutide 2.4 mg, a GLP-1 receptor agonist. CagriSema is semaglutide 2.4 mg plus cagrilintide 2.4 mg, an amylin analog, in one pen
- The trial weight-loss gap is roughly 7-8 percentage points: Wegovy ~14.9% (STEP 1) vs CagriSema ~22.7% (REDEFINE-1)
- The added weight loss comes from amylin signaling, a separate brainstem pathway, not from more semaglutide
- Wegovy has been FDA-approved since June 2021 and has substantial real-world and cardiovascular evidence. CagriSema is under FDA review as of May 2026
- CagriSema is investigational. FormBlends does not sell or supply CagriSema
Direct answer
Wegovy contains semaglutide alone, dosed at 2.4 mg once weekly. CagriSema contains the same semaglutide dose plus 2.4 mg of cagrilintide, a long-acting amylin analog, in a single weekly injection. The phase 3 trials report Wegovy at approximately 14.9% mean body-weight loss at 68 weeks and CagriSema at approximately 22.7% at 68 weeks. The added benefit comes from the cagrilintide component activating amylin receptors in the brainstem, not from a higher GLP-1 dose.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- What each medication actually contains
- The head-to-head numbers inside REDEFINE-1
- Why amylin adds 7 to 8 percentage points
- Side effects compared
- Cardiovascular and metabolic effects
- Regulatory status
- Insurance, cost, and access
- Who should stay on Wegovy if CagriSema launches
- The contrary view: is the added benefit worth the added complexity?
- FAQ
- Sources
What each medication actually contains
Wegovy. Once-weekly subcutaneous injection of semaglutide. The maintenance dose is 2.4 mg per week, reached via a five-step titration starting at 0.25 mg. Approved by the FDA in June 2021 for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity. Approved for adolescents 12 years and older in late 2022.
CagriSema. Once-weekly subcutaneous injection containing semaglutide 2.4 mg and cagrilintide 2.4 mg in a single pen. The titration schedule is similar to Wegovy's, with both components escalated in tandem. Under FDA review as of May 2026; not commercially available.
Both products are manufactured by Novo Nordisk. Both use the same general device platform and the same once-weekly schedule. The only meaningful pharmacological difference is the inclusion of cagrilintide in CagriSema.
The head-to-head numbers inside REDEFINE-1
REDEFINE-1 included a semaglutide-only arm, which gives the most credible internal comparison between CagriSema and what is effectively Wegovy.
| Arm | n | Mean weight change (68 weeks) |
|---|---|---|
| CagriSema | ~2,108 | ~ -22.7% |
| Semaglutide 2.4 mg (Wegovy equivalent) | ~526 | ~ -16.1% |
| Cagrilintide 2.4 mg | ~526 | ~ -11.8% |
| Placebo | ~257 | ~ -2.3% |
The internal comparison: CagriSema beat semaglutide alone by about 6.6 percentage points in the same trial, same protocol, same population. That's the cleanest measure of what cagrilintide adds when stacked onto semaglutide.
The cross-trial comparison to STEP 1 (Wegovy's pivotal trial, ~14.9%) shows a wider gap, about 7.8 percentage points. The difference between the internal and cross-trial gaps reflects population and protocol differences between STEP 1 and REDEFINE-1.
Either way, the magnitude of the added benefit is meaningful: roughly the difference between losing 30 pounds and losing 45 pounds for a 200-pound starting weight.
Why amylin adds 7 to 8 percentage points
Cagrilintide is not just "more of the same." It activates a different receptor system.
Amylin biology. Amylin is co-secreted with insulin by pancreatic beta cells in response to meals. Endogenous amylin acts at the area postrema in the brainstem, a region also involved in nausea and gastric signaling. The behavioral effects include increased satiety, slowed gastric emptying, and reduced glucagon. Cagrilintide is a synthetic long-acting amylin analog that allows once-weekly dosing.
Why combining with GLP-1 makes sense. GLP-1 and amylin both reduce appetite and slow gastric emptying, but through partially separate central circuits. Stacking them recruits both pathways. Animal models showed additive weight loss, with the added benefit roughly equal to the sum of the two effects rather than a strong synergy.
What the data actually showed. In REDEFINE-1, semaglutide alone produced ~16.1% weight loss. Cagrilintide alone produced ~11.8%. If the effects were perfectly additive, the combination would produce roughly the sum minus some overlap. The observed 22.7% is consistent with substantial but not complete additivity.
The simple framing: cagrilintide adds a second appetite-suppression mechanism that GLP-1 alone does not maximally recruit. The body has more than one way to feel full. The combination uses both.
Side effects compared
| Event | Wegovy (STEP 1) | CagriSema (REDEFINE-1) |
|---|---|---|
| Nausea (any) | ~44% | ~50-55% |
| Diarrhea | ~30% | ~25-30% |
| Vomiting | ~24% | ~25-30% |
| Constipation | ~24% | ~20-25% |
| Discontinuation for adverse events | ~7% | ~6% |
The pattern is similar in kind: dose-dependent gastrointestinal events that cluster in the dose-escalation phase and attenuate over time. CagriSema reports somewhat higher nausea rates, consistent with the amylin component's known interaction with brainstem nausea circuits. Discontinuation rates are similar to Wegovy's.
Other safety considerations:
- Pancreatitis: rare with both; signal not clearly elevated
- Gallbladder events: increased with rapid weight loss in both
- Thyroid C-cell tumor warning: GLP-1 class consideration applies to both
- Heart rate: small mean increase, both
- Hypoglycemia: rare without diabetes, both
Cardiovascular and metabolic effects
Wegovy has substantial cardiovascular data from the SELECT trial (Lincoff et al., NEJM 2023), which showed a 20% relative reduction in major adverse cardiovascular events in patients with established cardiovascular disease and obesity but without diabetes. In March 2024, the FDA expanded Wegovy's label to include cardiovascular risk reduction in adults with obesity and established cardiovascular disease.
CagriSema's cardiovascular evidence is still developing. REDEFINE-3 is the dedicated cardiovascular outcomes trial. Until that reads out, CagriSema's CV value rests on the semaglutide component sharing the same molecule that succeeded in SELECT.
Metabolic effects (HbA1c, blood pressure, lipids) generally track weight loss. CagriSema's larger weight-loss effect implies modestly larger metabolic effects, though the dedicated diabetes trial (REDEFINE-2) is the primary source for HbA1c-specific data.
Regulatory status
| Attribute | Wegovy | CagriSema |
|---|---|---|
| FDA approval | June 2021 (obesity) | Under review (May 2026) |
| Adolescent indication | December 2022 (ages 12+) | Not applicable yet |
| Cardiovascular indication | March 2024 (with established CV disease) | Not applicable yet |
| Available now | Yes | No |
| Compounded version (alternative) | Yes, where shortage permits | No legitimate route exists |
Insurance, cost, and access
Wegovy list price was approximately $1,349 per month in late 2024. Manufacturer savings cards and patient assistance lower the effective cost for many commercially insured patients. NovoCare Pharmacy launched a direct-to-consumer cash-pay option for Wegovy at a reduced price during 2024 and 2025.
Compounded semaglutide became widely available during 2022-2024 under FDA-tolerated shortage compounding, with prices in the $200-$400 per month range. After Wegovy was removed from the FDA shortage list, the compounding landscape contracted but did not disappear.
CagriSema's cost is unknown. The likely U.S. launch list price is comparable to or slightly above Wegovy's. Novo will almost certainly offer a savings program.
Insurance coverage for CagriSema will start narrow and broaden over 12 to 18 months, following the typical formulary cycle. Medicare Part D coverage for obesity remains constrained by statute, with limited carve-outs.
Who should stay on Wegovy if CagriSema launches
Wegovy will not become obsolete. Reasonable patient profiles to stay on Wegovy:
- Achieved adequate weight loss and metabolic improvement; no clinical reason to chase higher numbers
- Tolerated semaglutide reasonably well; reluctant to introduce a new variable with the cagrilintide component
- Cost-sensitive and Wegovy savings programs make it affordable
- On Wegovy for cardiovascular risk reduction; CagriSema does not yet have a parallel CV indication
- On compounded semaglutide for cost reasons; switching to a more expensive brand combination is not justified
Patient profiles where CagriSema, if approved, would be worth discussing:
- Plateaued on Wegovy short of the target
- Tolerating semaglutide well and willing to accept somewhat higher GI risk for additional weight loss
- Have not started obesity pharmacotherapy yet and want the strongest evidence-based option
The contrary view: is the added benefit worth the added complexity?
Three honest pushbacks to "CagriSema beats Wegovy."
Pushback 1: Marginal benefit, marginal patients. The 22.7% vs 14.9% gap looks dramatic, but for many patients, a 10-15% loss already produces meaningful health benefits and is reasonably durable. Adding another 7-8 percentage points has diminishing returns in terms of cardiometabolic outcomes and may add side-effect burden. Not every patient needs to chase the maximum number.
Pushback 2: Side effects compound. The combination produces somewhat higher GI rates. For a patient who barely tolerates semaglutide, swapping to CagriSema may produce nausea that crosses into unacceptable territory. Wegovy stays the better fit.
Pushback 3: Long-term durability is not yet established. Wegovy has 5+ years of post-approval data. CagriSema will have 68-week trial data plus extensions at U.S. launch. For a chronic medication, that asymmetry favors Wegovy until more data accumulates.
The fair conclusion: CagriSema produces more weight loss on average, but "more weight loss" is not the same as "better for every patient." Wegovy will remain the right choice for many.
Decision framework
If you are starting obesity pharmacotherapy now: Wegovy is the available branded option for semaglutide-based therapy. Zepbound (tirzepatide) is another approved option with comparable weight-loss magnitude to CagriSema. Starting today does not lock you out of CagriSema later if it becomes available.
If you are doing well on Wegovy: stay on Wegovy. There is no clinical reason to disrupt a working regimen for an incremental gain.
If you have plateaued on Wegovy and want more: the conversation is whether to switch to tirzepatide now, wait for CagriSema, or intensify behavioral support. Switching to tirzepatide now is the option with the most data and immediate availability.
If cost is the constraint: Wegovy, compounded semaglutide (if available legally in your situation), and patient-assistance programs are the levers. CagriSema is unlikely to be the cost-friendly option at launch.
Compounded medication note for this topic
For CagriSema vs Wegovy: The Real Difference Is the Amylin, keep the pharmacy distinction clear: when compounded semaglutide or tirzepatide is prescribed, it is prepared for an individual patient by a licensed 503A compounding pharmacy. Compounded preparations are not FDA-approved drug products and are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound.
The practical question is not whether a compounded medication is a brand substitute. It is whether the prescription, pharmacy label, concentration, follow-up plan, and adverse-event support are clear enough for your specific medical history.
FAQ
Is CagriSema just Wegovy with an extra ingredient? Yes, in essence. CagriSema is semaglutide 2.4 mg (the same as Wegovy) plus cagrilintide 2.4 mg, an amylin analog, in a single fixed-ratio injection.
Will Wegovy be discontinued when CagriSema launches? No. Novo Nordisk has not indicated any plan to discontinue Wegovy. The two products are designed to coexist.
How much more weight will I lose on CagriSema vs Wegovy? The trial average says roughly 7-8 percentage points more. Individual responses vary widely; some patients may see no additional benefit.
Does CagriSema have a generic version? No. Semaglutide and cagrilintide are both proprietary biologic compounds. Biosimilars for semaglutide are not yet U.S.-approved.
Will I need to titrate CagriSema like I did with Wegovy? Yes. The titration protocol will be similar, with both components escalated together to minimize GI effects.
Can I use Wegovy and cagrilintide separately? Cagrilintide is not commercially available as a standalone product. There is no legitimate retail route for separate administration.
Is CagriSema safer than Wegovy? Not clearly. Side-effect profiles are similar in kind; CagriSema shows slightly higher GI rates. Long-term safety is less established.
Will Medicare cover CagriSema? Same constraints as other anti-obesity medications. Medicare Part D does not cover obesity drugs for the obesity indication. A potential CV indication via REDEFINE-3 could change this for some patients.
Is CagriSema available as a daily pill? No. CagriSema is a once-weekly injection. Oral semaglutide (Rybelsus) is a separate product. There is no oral cagrilintide.
Does CagriSema cause more Ozempic face than Wegovy? "Ozempic face" reflects weight-loss-induced volume changes in the face. CagriSema produces more weight loss, so the facial volume change is likely to be more visible on average.
Will FormBlends carry CagriSema? FormBlends does not sell or supply CagriSema. CagriSema is investigational. Distribution channels at launch will be determined by Novo Nordisk.
Sources
- Garvey WT et al. CagriSema REDEFINE-1 Results. Presented at ObesityWeek 2024.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes (SELECT). New England Journal of Medicine. 2023.
- Lau DCW et al. Once-weekly cagrilintide for weight management: phase 2 trial. Lancet. 2021.
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo (STEP 4). JAMA. 2021.
- Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity and type 2 diabetes (STEP 2). Lancet. 2021.
- Kelly AS et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. New England Journal of Medicine. 2020.
- FDA. Wegovy Prescribing Information. Latest revision 2024.
- FDA. Cardiovascular Risk Reduction Indication Approval for Semaglutide 2.4 mg. March 2024.
- Endocrine Society. Pharmacological Management of Obesity Clinical Practice Guideline. 2024 update.
- Novo Nordisk Annual Report 2024. REDEFINE Program Pipeline Disclosure.
Footer disclaimers
Platform Disclaimer. FormBlends is a telehealth platform that helps connect patients with independent licensed clinicians and pharmacies. We do not manufacture or supply investigational medications including CagriSema. Treatment plans are designed by an independent prescriber based on individual evaluation.
Investigational Drug Notice. CagriSema is under FDA review as of May 2026 and is not commercially available in the United States. Wegovy is FDA-approved and available through standard pharmacy and telehealth channels.
Results Disclaimer. The percentage weight-loss figures cited reflect mean changes in controlled clinical trials with structured lifestyle intervention. Real-world outcomes commonly fall below trial averages due to differences in adherence, dose, and lifestyle support. Individual results vary.
Trademark Notice. Wegovy, Ozempic, Rybelsus, and Saxenda are registered trademarks of Novo Nordisk A/S. CagriSema is a Novo Nordisk development name. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →